M. Dysphagia Management - Brain Injury Association of
... patients who were not oriented to person, place and time as compared to those who were oriented. § Results were not significant for aspiration of puree. § Odds of being deemed unsafe for any oral intake were not ...
... patients who were not oriented to person, place and time as compared to those who were oriented. § Results were not significant for aspiration of puree. § Odds of being deemed unsafe for any oral intake were not ...
ACUTE HEART FAILURE
... This information in this Handbook is intended for use by and with experienced physicians and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Decisions about par ...
... This information in this Handbook is intended for use by and with experienced physicians and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Decisions about par ...
Diencephalic amnesia and apraxia after left thalamic infarction
... years (mean 29.2) who were examined neurologically and had visual evoked responses (VERs) performed in our department during the period 1973–83 were re-examined in 1983–85. Twenty six of the patients (32%) had progressed to probable or clinically definite multiple sclerosis during the follow up peri ...
... years (mean 29.2) who were examined neurologically and had visual evoked responses (VERs) performed in our department during the period 1973–83 were re-examined in 1983–85. Twenty six of the patients (32%) had progressed to probable or clinically definite multiple sclerosis during the follow up peri ...
Treating Inflammatory Bowel Disease with Biologics
... •At week 0, all patients received infliximab 5 mg/kg •Response recorded at week 2 and patients divided into 1 of 3 groups (patients followed until week 46) •Group I: placebo at weeks 2, 6, and then every 8 weeks •Group II: infliximab 5 mg/kg at weeks 2, 6, then every 8 weeks •Group III: infliximab 5 ...
... •At week 0, all patients received infliximab 5 mg/kg •Response recorded at week 2 and patients divided into 1 of 3 groups (patients followed until week 46) •Group I: placebo at weeks 2, 6, and then every 8 weeks •Group II: infliximab 5 mg/kg at weeks 2, 6, then every 8 weeks •Group III: infliximab 5 ...
U.S. Prescribing Information, including Boxed Warning
... Hematologic: The usual course of MUSTARGEN (total dose of 0.4 mg/kg either given as a single intravenous dose or divided into two or four daily doses of 0.2 or 0.1 mg/kg, respectively) generally produces a lymphocytopenia within 24 hours after the first injection; significant granulocytopenia occurs ...
... Hematologic: The usual course of MUSTARGEN (total dose of 0.4 mg/kg either given as a single intravenous dose or divided into two or four daily doses of 0.2 or 0.1 mg/kg, respectively) generally produces a lymphocytopenia within 24 hours after the first injection; significant granulocytopenia occurs ...
Provision of intraoperative diagnostic opinions and diagnostic
... service users. It would be important that access to an equivalent clinical or diagnostic service was identified by the clinical team for the patient such that no indirect discrimination of patients was implied. Indirect discrimination is when there is a condition, rule, policy or practice that appli ...
... service users. It would be important that access to an equivalent clinical or diagnostic service was identified by the clinical team for the patient such that no indirect discrimination of patients was implied. Indirect discrimination is when there is a condition, rule, policy or practice that appli ...
PDF - Molecular and Cellular Therapies
... clinical outcomes, which arose from the advantage provided by the protective film layer formed following application of the product. When using the Wipe formulation, the concentration of active ingredients reaching the affected area may be too low to achieve any beneficial effects. As Wipes were cle ...
... clinical outcomes, which arose from the advantage provided by the protective film layer formed following application of the product. When using the Wipe formulation, the concentration of active ingredients reaching the affected area may be too low to achieve any beneficial effects. As Wipes were cle ...
Optimizing Patient Outcomes - Advanced Studies in Medicine
... “My parents always remind me how grateful I should be that I only have mild CF” “I find just staying active is the most important thing to keep me healthy” ...
... “My parents always remind me how grateful I should be that I only have mild CF” “I find just staying active is the most important thing to keep me healthy” ...
INTERFERON a-2B MAY IMPAIR TESTICULAR HISTOLOGY
... The rats were divided into 3 groups: 6 rats received 7.500 units (5 MIU=m2) of interferon a-2B (Intron), considered in clinical treatment dose range, 3 times weekly for 3 weeks (low-dose interferon group). Six rats received 30.000 units (20 MIU=m2) of interferon a-2B (Intron), considered high treatm ...
... The rats were divided into 3 groups: 6 rats received 7.500 units (5 MIU=m2) of interferon a-2B (Intron), considered in clinical treatment dose range, 3 times weekly for 3 weeks (low-dose interferon group). Six rats received 30.000 units (20 MIU=m2) of interferon a-2B (Intron), considered high treatm ...
Osteopathic manual therapy versus conventional
... and T2, the best results were obtained in the OMT group: only the VAS value at T2 was not statistically significantly different between two groups (3.80 1.26 vs 4.40 1.75, P > 0.05) (Table 2). Improvement in values of VAS, MOV and ROM in both groups was observed at T1 and at T2 than at T0. A sta ...
... and T2, the best results were obtained in the OMT group: only the VAS value at T2 was not statistically significantly different between two groups (3.80 1.26 vs 4.40 1.75, P > 0.05) (Table 2). Improvement in values of VAS, MOV and ROM in both groups was observed at T1 and at T2 than at T0. A sta ...
PART 6: CHEMOTHERAPEUTIC DRUGS Anti
... The cephalosporins are β-lactam antibiotics that are closely related both structurally and functionally to the penicillins. Most cephalosporins are produced semisynthetically.Cephalosporins have the same mode of action as penicillins, and they are affected by the same resistance mechanisms. However, ...
... The cephalosporins are β-lactam antibiotics that are closely related both structurally and functionally to the penicillins. Most cephalosporins are produced semisynthetically.Cephalosporins have the same mode of action as penicillins, and they are affected by the same resistance mechanisms. However, ...
No one is an island - Charme S. Davidson
... the family system; MFT reduces crises that could cause additional splitting. i. The model is effective and was the first to be offered. ii. In only two places (4 & 5a) does the MFT benefit the family; generally, its function is to serve the identified patient. b. Even though couples and FOC can appe ...
... the family system; MFT reduces crises that could cause additional splitting. i. The model is effective and was the first to be offered. ii. In only two places (4 & 5a) does the MFT benefit the family; generally, its function is to serve the identified patient. b. Even though couples and FOC can appe ...
2
... inhibitors are unlikely to be helpful because the drugs are not expected to reach the consolidated lungs. For hospitalised patients with suspected or confirmed H7N9 influenza, both oral oseltamivir and intravenous zanamivir are currently considered to be acceptable alternatives for therapy [6, 7]. A ...
... inhibitors are unlikely to be helpful because the drugs are not expected to reach the consolidated lungs. For hospitalised patients with suspected or confirmed H7N9 influenza, both oral oseltamivir and intravenous zanamivir are currently considered to be acceptable alternatives for therapy [6, 7]. A ...
Acute Coronary Syndrome (ACS)
... Importance: The goals of therapy after STE-ACS are to restore th patent to normal activities to the extent possible and to use the acute even to re-evaluate the plan of care, particularly lifestyle and risk factor modification. This is a teachable moment. GUIDELINE: 6.2 Medical regimen and use of Me ...
... Importance: The goals of therapy after STE-ACS are to restore th patent to normal activities to the extent possible and to use the acute even to re-evaluate the plan of care, particularly lifestyle and risk factor modification. This is a teachable moment. GUIDELINE: 6.2 Medical regimen and use of Me ...
Oral erythromycin for gastroparesis
... calcium-channel-blocker, amlodipine. There have been many combination antihypertensive agents approved by FDA over the last year or so. Combination products may decrease “pill burden” since many hypertensive patients require multiple medications to control their blood pressure. Tekamlo®’s labeled in ...
... calcium-channel-blocker, amlodipine. There have been many combination antihypertensive agents approved by FDA over the last year or so. Combination products may decrease “pill burden” since many hypertensive patients require multiple medications to control their blood pressure. Tekamlo®’s labeled in ...
ToxTidbits: Antidote Facts
... effects associated with the use of IFEs have mostly been reported in patients receiving them as part of parenteral nutrition regimens and have included hypertriglyceridemia, acute pancreatitis, cholestasis and increased risk of infection. Rapid infusions of IFE have the potential to induce fat (cont ...
... effects associated with the use of IFEs have mostly been reported in patients receiving them as part of parenteral nutrition regimens and have included hypertriglyceridemia, acute pancreatitis, cholestasis and increased risk of infection. Rapid infusions of IFE have the potential to induce fat (cont ...
A i rway Cl ear ance
... Recombinant human DNase (Pulmozyme, Genentech, South San Francisco, CA), when given as an aerosol in a dose of 2.5 mg once or twice a day to patients with CF, led to a moderate but significant decrease in dyspnea, a reduction in costs related to exacerbations of respiratory symptoms, and a modest im ...
... Recombinant human DNase (Pulmozyme, Genentech, South San Francisco, CA), when given as an aerosol in a dose of 2.5 mg once or twice a day to patients with CF, led to a moderate but significant decrease in dyspnea, a reduction in costs related to exacerbations of respiratory symptoms, and a modest im ...
Cardio - Renal Syndrome ( CRS )
... therapy, although available data do not clearly support favourable effects on kidney function. Rather than improving renal function, dopamine has been shown to impair renal oxygen kinetics, inhibit feedback systems that protect the kidney from ischemia, and possibly worsen tubular injury low-dose do ...
... therapy, although available data do not clearly support favourable effects on kidney function. Rather than improving renal function, dopamine has been shown to impair renal oxygen kinetics, inhibit feedback systems that protect the kidney from ischemia, and possibly worsen tubular injury low-dose do ...
Frontal-Temporal Dementias
... Dementia means a progressive decline in cognitive and behavioral competence, compared to former abilities. Many diseases can cause dementia. Degenerative dementia is a permanent, incurable state caused by diseases that kill brain cells progressively. Each disease usually starts in a different part o ...
... Dementia means a progressive decline in cognitive and behavioral competence, compared to former abilities. Many diseases can cause dementia. Degenerative dementia is a permanent, incurable state caused by diseases that kill brain cells progressively. Each disease usually starts in a different part o ...
C - G-Care
... Suspect that the diarrhoea may have an infective cause where there is no clear alternative cause for diarrhoea (drugs eg laxatives, underlying bowel disease) – if you suspect CDI on clinical grounds, start treatment for CDI empirically pending test results and then review that treatment when the res ...
... Suspect that the diarrhoea may have an infective cause where there is no clear alternative cause for diarrhoea (drugs eg laxatives, underlying bowel disease) – if you suspect CDI on clinical grounds, start treatment for CDI empirically pending test results and then review that treatment when the res ...
Perlane Terumo_PI 04-13-09.indd - Cosmetic Surgery Specialists of
... the glabellar area. It is thought to result from the injury, obstruction, or compromise of blood vessels. • Delayed onset inflammatory papules have been reported following the use of dermal fillers. Inflammatory papules that may occur rarely should be considered and treated as a soft tissue infect ...
... the glabellar area. It is thought to result from the injury, obstruction, or compromise of blood vessels. • Delayed onset inflammatory papules have been reported following the use of dermal fillers. Inflammatory papules that may occur rarely should be considered and treated as a soft tissue infect ...
Clinical Update - July 2009 - MC2024-0709
... recently established 3 criteria that support a diagnosis of EoE. • Presence of esophageal symptoms. In adult patients, this is primarily solid food dysphagia. Children may have various symptoms, including chest pain, vomiting, dysphagia, and heartburn. • Presence of 15 or more eosinophils/high-power ...
... recently established 3 criteria that support a diagnosis of EoE. • Presence of esophageal symptoms. In adult patients, this is primarily solid food dysphagia. Children may have various symptoms, including chest pain, vomiting, dysphagia, and heartburn. • Presence of 15 or more eosinophils/high-power ...
AADC Gene Therapy for Parkinson`s Disease
... a gene, AADC (aromatic amino acid decarboxylase) into the brains of people with moderately advanced Parkinson’s disease. In this study, the AADC gene will be delivered to a specific area of the brain and it may increase dopamine production in the brain. It is the third study of its kind. The study w ...
... a gene, AADC (aromatic amino acid decarboxylase) into the brains of people with moderately advanced Parkinson’s disease. In this study, the AADC gene will be delivered to a specific area of the brain and it may increase dopamine production in the brain. It is the third study of its kind. The study w ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.